Cite
APA Citation
Powles, T., Nickles, D., Van Allen, E., Chappey, C., Zou, W., Kowanetz, M., Kadel, E., Denker, M., Boyd, Z., Vogelzang, N., Kim, J., Bellmunt, J., Loriot, Y., Drake, C., O'Hear, C., Fasso, M., Hegde, P., & Mariathasan, S. (2015). immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal for immunotherapy of cancer, 3(2), 1–2. http://access.bl.uk/ark:/81055/vdc_100080441580.0x0001e0